Trial · NCT04577001
Letrozole in Patients With Hepatopulmonary Syndrome
NCT04577001, Phase 2, Terminated, Mayo Clinic; results first posted 2024-05-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Letrozole in Patients With Hepatopulmonary Syndrome. Trials, record NCT04577001. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04577001
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Letrozole in Patients With Hepatopulmonary Syndrome
- NCT number
- NCT04577001
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 1 participants, actual
- Lead sponsor
- Mayo Clinic
- Conditions
- Hepatopulmonary Syndrome
- Interventions
- Letrozole, Placebo
- First posted
- 2020-10-06
- Last updated
- 2024-05-14
- Results first posted
- 2024-05-14
- Limitations and caveats
- Terminated study due to low recruitment numbers.
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Alveolar-Arterial Oxygen | 6 months | To determine whether letrozole affects alveolar-arterial oxygen gradient (AaPO2) at 6 months in patients with HPS. |
| Secondary | Hormone Levels | 6 months | To determine whether letrozole affects estradiol, progesterone, testosterone levels at 6 months |
| Secondary | Oxygen Saturation | 3 and 6 months | To determine whether letrozole affects oxygen saturation from pulse oximetry at 3 months 6 months and distance walked in 6 minutes in patients with HPS |
| Secondary | Side Effects | 6 months | To determine the safety and adverse effects associated with letrozole administration in patients with HPS |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Alveolar-Arterial Oxygen | 6 months | Study terminated due to low recruitment numbers. Data was not collected on the one enrolled participant for this outcome measure due to withdrawal after becoming ineligible prior to outcome measure timeframe completion. | ||
| SECONDARY | Hormone Levels | 6 months | Study terminated due to low recruitment numbers. Data was not collected on the one enrolled participant for this outcome measure due to withdrawal after becoming ineligible prior to outcome measure timeframe completion. | ||
| SECONDARY | Oxygen Saturation | 3 and 6 months | Study terminated due to low recruitment numbers. Data was not collected on the one enrolled participant for this outcome measure due to withdrawal after becoming ineligible prior to outcome measure timeframe completion. | ||
| SECONDARY | Side Effects | 6 months | Study terminated due to low recruitment numbers. Data was not collected on the one enrolled participant for this outcome measure due to withdrawal after becoming ineligible prior to outcome measure timeframe completion. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Letrozole Group | 0 | |
| Overall Study | STARTED | Placebo Group | 1 | |
| Overall Study | COMPLETED | Letrozole Group | 0 | |
| Overall Study | COMPLETED | Placebo Group | 0 | |
| Overall Study | NOT COMPLETED | Letrozole Group | 0 | |
| Overall Study | NOT COMPLETED | Placebo Group | 1 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Letrozole Group | 0 | 0 |
| Total, all-cause mortality | Placebo Group | 0 | 1 |
| Total, other adverse events | Letrozole Group | 0 | 0 |
| Total, other adverse events | Placebo Group | 0 | 1 |
| Total, serious adverse events | Letrozole Group | 0 | 0 |
| Total, serious adverse events | Placebo Group | 0 | 1 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04577001
GET https://conductscience.org/api/trials/v1/NCT04577001/registered